Sun Pharma reports profit dip due to Organon acquisition charge, specialty sales rise
Sun Pharmaceutical Industries' Q2 net profit fell to 19.89 billion rupees, impacted by a one-time charge linked to its planned Organon purchase, while specialty drug sales grew 6.9%.
India's leading drugmaker by revenue posted a consolidated net profit of 19.89 billion rupees ($209 million) for the quarter ended September 30, down from 31.18 billion rupees a year earlier. The decline reflects a one-time charge of 12.69 billion rupees tied to costs associated with its planned acquisition of Organon and provisions related to India's labour code framework. Excluding the charge, profit rose 6.3% to 44.28 billion rupees.
Revenue increased nearly 12% to 161.99 billion rupees, beating analysts' average estimate of 158.25 billion rupees. Specialty drug sales, which the company is expanding to offset pressure in the U.S. market, grew 6.9% to $356 million, representing 21.1% of total sales. Growth was driven by a 17.3% rise in Indian sales, the firm's largest market, while U.S. sales fell 8.2%.
Following the earnings release, Sun Pharma's shares rose 4.2% to 1,835 rupees.